Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.20.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
$ / shares in Units, shares in Thousands
1 Months Ended 3 Months Ended
Dec. 31, 2018
USD ($)
Mar. 31, 2020
USD ($)
position
$ / shares
shares
Mar. 31, 2019
USD ($)
shares
Jan. 01, 2020
USD ($)
Dec. 31, 2019
USD ($)
Property, Plant and Equipment [Line Items]          
Revenue recognized from milestone method revenue   $ 400,000 $ 1,300,000    
Number of positions in an unrealized loss position | position   40      
Credit losses related to available-for-sale debt securities   $ 0      
Allowance for credit loss       $ 5,500,000  
Increase (decrease) to allowance for credit loss during period   500,000      
Investment in Viking common stock   28,258,000     $ 48,425,000
Investment in warrants   $ 4,621,000     9,910,000
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares   10,144 7,015    
COVID-19          
Property, Plant and Equipment [Line Items]          
Increase (decrease) in allowance for credit losses   $ 200,000      
Share-based Compensation          
Property, Plant and Equipment [Line Items]          
Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares) | shares   600      
Adjustment          
Property, Plant and Equipment [Line Items]          
Stockholders' equity       $ 5,200,000  
Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Outstanding warrants to purchase shares of Viking's common stock (shares) | shares   1,500      
Warrant exercise price (USD per share) | $ / shares   $ 1.50      
Royalty Agreements | Aziyo          
Property, Plant and Equipment [Line Items]          
Effective interest rate for forecasted cash flows (as a percent)   23.00%      
Commercial license rights          
Property, Plant and Equipment [Line Items]          
Definite lived intangible assets   $ 38,298,000     38,298,000
Commercial license rights | Palvella          
Property, Plant and Equipment [Line Items]          
Contract asset $ 8,000,000.0        
Definite lived intangible assets $ 10,000,000.0 $ 10,000,000     $ 10,000,000
Minimum | Royalty Agreements | Palvella          
Property, Plant and Equipment [Line Items]          
Tiered royalty rate (as a percent) 5.00%        
Maximum | Royalty Agreements | Palvella          
Property, Plant and Equipment [Line Items]          
Tiered royalty rate (as a percent) 9.80%